Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | QDPR | P09417 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.43 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.42 |
| ▸ | SPR | P35270 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28218450 | 0.91 | RAB9A (0.49) | NPC1PARP10PARP14SCD5SPR | |
| SCHEMBL2651932 | 0.86 | QDPR (0.60) | KCNH2HRH3QDPRPARP10ALDH1A1 | |
| SCHEMBL1440137 | 0.84 | ALDH1A1 (0.47) | PARP10PARP14ALDH1A1 | |
| SCHEMBL1558037 | 0.83 | DRD2 (0.58) | QDPRMGLL | |
| SCHEMBL1531725 | 0.81 | KCNH2 (0.59) | NPC1CA12CA1CA2CA7 | |
| SCHEMBL2637025 | 0.81 | NPC1 (0.61) | NPC1PARP10PARP14SCD5RAB9A | |
| SCHEMBL6251685 | 0.81 | NPC1 (0.45) | NPC1CA12CA1CA2CA7 | |
| SCHEMBL18585948 | 0.81 | HDAC4 (0.50) | NPC1KCNH2HRH3QDPRKMO | |
| SCHEMBL4405378 | 0.81 | TPSAB1 (0.58) | KCNH2 | |
| SCHEMBL2961077 | 0.80 | SPR (0.54) | NPC1CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1602191-A | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2005-03-30 | — | — | CN | claimed |
| US-20240158418-A1 | EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS | C4 THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4347044-A2 | EGFR DEGRADERS TO TREAT CANCER METASTASIS TO THE BRAIN OR CNS | C4 Therapeutics, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240076300-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | US | disclosed |
| US-11673902-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2021127561-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| CN-105849096-B | Piperidine derivatives having multimodal activity against pain | 埃斯蒂文制药股份有限公司 | 2019-11-29 | — | — | CN | disclosed |
| CN-105849096-A | Piperidine derivatives having multimodal activity against pain | 埃斯蒂文博士实验室股份有限公司 | 2016-08-10 | — | — | CN | disclosed |
| EP-2885291-A1 | VEGFR3 INHIBITORS | Cancer Therapeutics Crc Pty Limited (AU) | 2015-06-24 | — | — | EP | disclosed |
| US-20060079683-A1 | Arylthiobenzylpiperidine derivatives | H. LUNDBECK A/S (DK) | 2006-04-13 | — | — | US | disclosed |
| US-20060079523-A1 | N-[3-(1-{[4-(4-fluorophenylthio)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide; melatonin-concentrating hormone (MCH1) receptor ligand; antidepressant, anxiolytic, antidiabetic agent | H. LUNDBECK A/S | 2006-04-13 | — | — | US | disclosed |
| US-20060079522-A1 | Amino substituted aryloxybenzylpiperidine derivatives | H. LUNDBECK A/S (DK) | 2006-04-13 | — | — | US | disclosed |
| US-20060079524-A1 | Amino substituted aryloxybenzylpiperidine derivatives | H. LUNDBECK A/S | 2006-04-13 | — | — | US | disclosed |
| WO-2006017443-A2 | ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| EP-1590326-A2 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | H. Lundbeck A/S (DK) | 2005-11-02 | — | — | EP | disclosed |
| CN-1602191-A | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2005-03-30 | — | — | CN | disclosed |
| WO-2004064764-A2 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | H. LUNDBECK A/S (DK) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004064774-A2 | DNA ENCODING A HUMAN MELANIN CONCENTRATING HORMONE RECEPTOR (MCH1) AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20030077701-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158418-A1 | EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS | EGFR, ERBB2, ERBB3 | NPC1 2686/4885CA12 2452/4885CA1 3242/4885 |
| US-20060079524-A1 | Amino substituted aryloxybenzylpiperidine derivatives | MCHR1, MCHR2, MC4R | NPC1 255/4885CA12 4676/4885CA1 4707/4885 |
| US-20060079523-A1 | N-[3-(1-{[4-(4-fluorophenylthio)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide; melatonin-concentrating hormone (MCH1) receptor ligand; antidepressant, anxiolytic, antidiabetic agent | MCHR1, MTNR1A, MTNR1B | NPC1 453/4885CA12 4432/4885CA1 4215/4885 |
| US-20030077701-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | NPC1 1498/4885CA12 2846/4885CA1 2394/4885 |
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | NPC1 2309/4885CA12 4577/4885CA1 4843/4885 |
| US-20060079683-A1 | Arylthiobenzylpiperidine derivatives | MCHR1, MC4R, MCHR2 | NPC1 211/4885CA12 4634/4885CA1 4689/4885 |
| US-20240076300-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | NPC1 2309/4885CA12 4577/4885CA1 4843/4885 |
| US-20060079522-A1 | Amino substituted aryloxybenzylpiperidine derivatives | MCHR1, MCHR2, MC4R | NPC1 248/4885CA12 4644/4885CA1 4703/4885 |
| US-11673902-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | NPC1 2309/4885CA12 4577/4885CA1 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.